← Leaderboards
Sanaz Memarzadeh
Va Greater Los Angeles Healthcare System
$2,760,611
Attributed
$3,449,281
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $695.8K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,449,281 · 4
VA$0 · 4
By mechanism
R01$3,128,147 · 2
U54$321,134 · 2
I01$0 · 3
IK2$0 · 1
Top collaborators
- Yi Xing2 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoTumorWomanMouse ModelResistanceResponseChemotherapyCellsClinical TrialsMalignant NeoplasmsPharmaceutical PreparationsBaseMediatingEndometrial NeoplasmsEndometrial CarcinomaLaboratoriesBackMalignant Female Reproductive System NeoplasmPten GeneCancer PatientCollaborationsHormonesEstrogensPathway Interactions
Grant awards (26)
Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer$681,544
R01 · FY2025 · CA · contact PI
BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer Cells$0
I01 · FY2025 · VA · contact PI
Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer$695,797
R01 · FY2024 · CA · contact PI
Exploring super charged NK cells as a novel cell-based immune therapy in targeting platinum resistant ovarian cancers$0
I01 · FY2024 · VA · contact PI
BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer Cells$0
I01 · FY2024 · VA · contact PI
Reactivating p53 Function with a Novel Structure-based Peptide as a Therapeutic Approach for Overcoming Platinum Resistance$0
I01 · FY2023 · VA · contact PI
BCCMA: Overcoming chemoresistance in ovarian cancer: Targeting Unique Vulnerabilities in Neuroendocrine-like Ovarian Cancer Cells$0
I01 · FY2023 · VA · contact PI
Reactivating p53 Function with a Novel Structure-based Peptide as a Therapeutic Approach for Overcoming Platinum Resistance$0
I01 · FY2022 · VA · contact PI
Reactivating p53 Function with a Novel Structure-based Peptide as a Therapeutic Approach for Overcoming Platinum Resistance$0
I01 · FY2021 · VA · contact PI
Reactivating p53 Function with a Novel Structure-based Peptide as a Therapeutic Approach for Overcoming Platinum Resistance$0
I01 · FY2020 · VA · contact PI
Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer$341,706
R01 · FY2019 · CA · contact PI
Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer$352,275
R01 · FY2018 · CA · contact PI
Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer$352,275
R01 · FY2017 · CA · contact PI
PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors$60,125
U54 · FY2017 · CA · contact PI
PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors$53,813
U54 · FY2017 · CA · contact PI
Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer$352,275
R01 · FY2016 · CA · contact PI
PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors$62,030
U54 · FY2016 · CA · contact PI
PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors$53,813
U54 · FY2016 · CA · contact PI
Pathobiology and Mechanism of Progesterone Resistance in Human Endometrial Cancer$352,275
R01 · FY2015 · CA · contact PI
PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors$53,813
U54 · FY2015 · CA · contact PI
PARP inhibition with hormonal modulation as a therapy for PTEN driven endometrial tumors$37,540
U54 · FY2015 · CA · contact PI
Role of estrogen receptor in endometrial cancer initiation and progression$0
IK2 · FY2015 · VA · contact PI
Role of estrogen receptor in endometrial cancer initiation and progression$0
IK2 · FY2014 · VA · contact PI
Role of estrogen receptor in endometrial cancer initiation and progression$0
IK2 · FY2013 · VA · contact PI
Role of estrogen receptor in endometrial cancer initiation and progression$0
IK2 · FY2012 · VA · contact PI
Role of estrogen receptor in endometrial cancer initiation and progression$0
IK2 · FY2011 · VA · contact PI